Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Alzheimer s & Dementia

Combined use of plasma p‐tau217, NfL, and GFAP predicts domain‐specific cognitive decline in cognitively unimpaired and MCI individuals

View Full Paper
Ask AI
Bookmark
Share

Authors

CWChao‐Yi WuCLChen LiuHFHadia Fatima

Discussion

Loading...

Member takes

Overview

Combined use of biomarkers predicts cognitive decline in individuals with mild cognitive impairment, suggesting targeted interventions may be beneficial.

Key Points

  • High levels of biomarkers predict cognitive decline, specifically impacting episodic and semantic memory.
  • Participants with mild cognitive impairment show significant decline, especially with elevated glial fibrillary acidic protein.
  • Assessment utilized Gaussian mixture models to classify biomarker levels in participants with Alzheimer's disease.
  • Finding highlights the need to focus on cognitive domains vulnerable to decline, even when overall cognition appears stable.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/6930dc6bea1aef094cca1ecdhttps://doi.org/10.1002/alz.70934
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plasma P‐tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline2025 · 17 citations
  2. 2Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients2024 · 21 citations
  3. 3Relative importance of blood-based biomarkers for Alzheimer’s disease-specific neurodegeneration and cognitive decline2026 · 1 citations
  4. 4Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort2025 · 8 citations
  5. 5Plasma p‐tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic2025 · 17 citations